Alasdair Coles

Alasdair Coles

UNVERIFIED PROFILE

Are you Alasdair Coles?   Register this Author

Register author
Alasdair Coles

Alasdair Coles

Publications by authors named "Alasdair Coles"

Are you Alasdair Coles?   Register this Author

93Publications

1649Reads

12Profile Views

Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.

J Neurol 2019 Jun 20;266(6):1539-1540. Epub 2019 Mar 20.

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-019-09288-yDOI Listing
June 2019

Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.

Mult Scler 2019 Jun 6:1352458519852093. Epub 2019 Jun 6.

NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK; National Institute for Health Research (NIHR), University College London Hospitals (UCLH) Biomedical Research Centre, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458519852093DOI Listing
June 2019

Promoting remyelination in multiple sclerosis.

J Neurol 2019 Jun 12. Epub 2019 Jun 12.

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-019-09421-xDOI Listing
June 2019

Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1).

J Neurol Neurosurg Psychiatry 2019 Mar 11;90(3):365-367. Epub 2018 Jun 11.

Department of Clinical Neurosciences, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2018-318124DOI Listing
March 2019

A case of anaphylaxis to alemtuzumab.

J Neurol 2019 Mar 4;266(3):780-781. Epub 2019 Feb 4.

Department of Clinical Neurosciences, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-019-09214-2DOI Listing
March 2019

Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.

Eye (Lond) 2019 02 29;33(2):223-229. Epub 2018 Nov 29.

Thyroid Eye Disease Service, Department of Ophthalmology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41433-018-0282-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367353PMC
February 2019

Sarcoidosis following alemtuzumab treatment for multiple sclerosis.

Mult Scler 2018 11 11;24(13):1779-1782. Epub 2018 Oct 11.

Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University and University Hospital of Wales, Cardiff, UK; Department of Neurology, University Hospital of Wales, Cardiff, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458518790391DOI Listing
November 2018

Alemtuzumab as Treatment for Multiple Sclerosis.

Cold Spring Harb Perspect Med 2018 10 1;8(10). Epub 2018 Oct 1.

Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a032029DOI Listing
October 2018

Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Authors:
Alasdair J Coles

Neurology 2018 09;91(12):581-582

(Cambridge, UK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006203DOI Listing
September 2018

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.

J Clin Endocrinol Metab 2018 08;103(8):3010-3018

University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-00359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097600PMC
August 2018

Women on multiple sclerosis clinical trial steering committees.

Ann Neurol 2018 08 9;84(2):329-330. Epub 2018 Sep 9.

School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25306DOI Listing
August 2018

Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.

Neurology 2018 05 30;90(18):849-851. Epub 2018 Mar 30.

From the Department of Neurology (M.S., P.J.T.), Helsinki University Hospital; Division of Clinical Neurosciences (M.S.-H., L.A.), Turku University Hospital, Finland; Department of Neurology (K.S., J.J., A.C.), Addenbrookes Hospital, University of Cambridge, UK; and Department of Neurology (J.T.S.), Vaasa Central Hospital, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000005420DOI Listing
May 2018

Authorship of phase 3 trials in multiple sclerosis.

Authors:
Alasdair Coles

Ann Neurol 2018 04;83(4):653-655

Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ana.25203
Publisher Site
http://dx.doi.org/10.1002/ana.25203DOI Listing
April 2018

Hypothyroid ataxia complicating monoclonal antibody therapy.

Pract Neurol 2017 Dec 4;17(6):482-484. Epub 2017 Aug 4.

Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/practneurol-2017-001713DOI Listing
December 2017

Physician-assisted death should be available to people with MS - Commentary.

Authors:
Alasdair Coles

Mult Scler 2017 11 1;23(13):1681. Epub 2017 Sep 1.

Department of Neurology, Addenbrookes Hospital, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517730133DOI Listing
November 2017

A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers.

J Neuroimmunol 2017 11 24;312:4-7. Epub 2017 Aug 24.

Concord Repatriation General Hospital, Hospital Road, Concord, New South Wales 2139, Australia; The University of Sydney, Camperdown, NSW, Australia 2006. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2017.08.009DOI Listing
November 2017

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Neurology 2017 Sep 23;89(11):1107-1116. Epub 2017 Aug 23.

From the Department of Neurology and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic; NeuroRx Research (D.L.A.), Montréal; Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; MS Clinic of Central Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK; Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, University Hospital Zürich and University of Zürich, Switzerland; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; The University of British Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595278PMC
September 2017

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Neurology 2017 Sep 23;89(11):1117-1126. Epub 2017 Aug 23.

From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary University of London (G.G.), Barts and the London School of Medicine, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles University and General Hospital in Prague, Czech Republic; Neuroimmunology and Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital Zürich and University of Zürich, Switzerland; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; The University of British Columbia (A.T.), Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montréal; Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada. M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004354DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595276PMC
September 2017

Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

JCI Insight 2017 Aug 17;2(16). Epub 2017 Aug 17.

JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.93739DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621870PMC
August 2017

Progressive multifocal leucoencephalopathy with Behçet's disease: an insight into pathophysiology.

Rheumatology (Oxford) 2017 Apr;56(4):668-670

Department of Medicine, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kew404DOI Listing
April 2017

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

Neurology 2017 03 8;88(10):1004-1006. Epub 2017 Feb 8.

From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003694DOI Listing
March 2017

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Neurology 2016 Nov 12;87(19):1985-1992. Epub 2016 Oct 12.

From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA; and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted).

View Article

Download full-text PDF

Source
http://www.neurology.org/lookup/doi/10.1212/WNL.000000000000
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000003319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109953PMC
November 2016

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Neurology 2016 Oct 2;87(14):1464-1472. Epub 2016 Sep 2.

From NeuroRx Research (D.L.A.) and Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Department of Biomedical Engineering (E.F.) and Mellen Center (J.A.C.), Cleveland Clinic, OH; Zagreb Medical School and University Hospital Center (V.V.B.), Croatia; Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Queen Mary University of London (G.G.), Barts and the London School of Medicine, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; Clinical Centre Kragujevac (M.S.), Clinic of Neurology, Serbia; Brigham and Women's Hospital Center for Neurologic Diseases (H.L.W.), Boston, MA; Sanofi Genzyme (S.L.L., D.H.M., M.A.P.), Cambridge, MA; and Evidence Scientific Solutions (D.R.T.), Horsham, West Sussex, UK. Dr. Panzara is currently with Wave Life Sciences, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075976PMC
October 2016

Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.

J Neurol Sci 2016 Apr 12;363:188-94. Epub 2016 Feb 12.

Sanofi Genzyme, Cambridge, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2016.02.025DOI Listing
April 2016

Parkinson's Disease, Religion, and Spirituality.

Mov Disord Clin Pract 2015 Dec 15;2(4):341-346. Epub 2015 Jul 15.

Department of Clinical Neurosciences Clifford Allbutt Building Cambridge Biomedical Campus Cambridge United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178734PMC
December 2015

Newer therapies for multiple sclerosis.

Authors:
Alasdair Coles

Ann Indian Acad Neurol 2015 Sep;18(Suppl 1):S30-4

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0972-2327.164824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604695PMC
September 2015

Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes.

J Neurol Neurosurg Psychiatry 2015 Jul 22;86(7):708-13. Epub 2014 Sep 22.

National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK Neurosciences Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://jnnp.bmj.com/content/86/7/708.full.pdf
Web Search
http://jnnp.bmj.com/cgi/doi/10.1136/jnnp-2014-308736
Publisher Site
http://dx.doi.org/10.1136/jnnp-2014-308736DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055984PMC
July 2015

Timing is everything in the treatment of multiple sclerosis.

BMJ Case Rep 2015 Apr 15;2015. Epub 2015 Apr 15.

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2014-208960DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401937PMC
April 2015

Mode of action and clinical studies with alemtuzumab.

Exp Neurol 2014 Dec 2;262 Pt A:37-43. Epub 2014 May 2.

Dept. of Clinical Neurosciences, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2014.04.018DOI Listing
December 2014

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

J Neurol Neurosurg Psychiatry 2014 Jul 24;85(7):795-8. Epub 2013 Dec 24.

Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2013-307042DOI Listing
July 2014

Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis.

J Neuroimmunol 2014 Jun 21;271(1-2):66-8. Epub 2014 Mar 21.

Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2014.03.012DOI Listing
June 2014

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.

Neurology 2014 Jun 16;82(24):2158-64. Epub 2014 May 16.

From the Department of Clinical Neurosciences (O.K.-E., L.A., O.T., A. Compston, A. Coles, J.J.) and the Centre for Applied Medical Statistics, Department of Public Health and Primary Care (R.A.P.), University of Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113466PMC
June 2014

Product licences for alemtuzumab and multiple sclerosis.

Lancet 2014 Mar;383(9920):867-8

Department of Clinical Neurosciences, University Neurology Unit, Cambridge CB2 0QQ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(14)60440-2DOI Listing
March 2014

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.

Proc Natl Acad Sci U S A 2013 Dec 26;110(50):20200-5. Epub 2013 Nov 26.

Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1313654110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864306PMC
December 2013

Immune competence after alemtuzumab treatment of multiple sclerosis.

Neurology 2013 Sep 7;81(10):872-6. Epub 2013 Aug 7.

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3182a35215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885219PMC
September 2013

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

Drug Des Devel Ther 2013 6;7:131-8. Epub 2013 Mar 6.

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S32687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593763PMC
June 2013

The outlook for alemtuzumab in multiple sclerosis.

BioDrugs 2013 Jun;27(3):181-9

Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Box 165, Cambridge, CB2 0QQ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-013-0028-3DOI Listing
June 2013

Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.

Ther Adv Chronic Dis 2013 May;4(3):97-103

Department of Clinical Neurosciences, University of Cambridge, Level 6, Block A, Box 165, Addenbrookes Hospital, Hills Road, Cambridge CB2 0QQ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040622313479137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629751PMC
May 2013

Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.

Mult Scler 2013 Feb 5;19(2):241-4. Epub 2012 Apr 5.

Department of Clinical Neurosciences, University of Cambridge, Level 6 A Block, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK.

View Article

Download full-text PDF

Source
http://msj.sagepub.com/cgi/doi/10.1177/1352458512444915
Publisher Site
http://dx.doi.org/10.1177/1352458512444915DOI Listing
February 2013

Alemtuzumab treatment of multiple sclerosis.

Authors:
Alasdair J Coles

Semin Neurol 2013 Feb 25;33(1):66-73. Epub 2013 May 25.

Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, England, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0033-1343797DOI Listing
February 2013

Alemtuzumab therapy for multiple sclerosis.

Authors:
Alasdair J Coles

Neurotherapeutics 2013 Jan;10(1):29-33

Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-012-0159-0
Publisher Site
http://dx.doi.org/10.1007/s13311-012-0159-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557360PMC
January 2013

Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis.

Mult Scler Relat Disord 2013 Jan 25;2(1):60-3. Epub 2012 Sep 25.

Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2012.07.002DOI Listing
January 2013

We are about to cure MS in the next 10 years, even though we do not know its cause: no.

Authors:
Alasdair Coles

Mult Scler 2012 Jun;18(6):784-5

Department of Clinical Neuroscience, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458512446522DOI Listing
June 2012

An evolving case of headaches and strokes.

Pract Neurol 2011 Apr;11(2):113-7

Academic Foundation Trainee in Neurosciences, Department of Clinical Neurosciences, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp.2011.242206DOI Listing
April 2011

New treatment strategies in multiple sclerosis.

Exp Neurol 2010 Sep 12;225(1):34-9. Epub 2010 Jun 12.

Dept. of Clinical Neurosciences, Box 165 Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK.

View Article

Download full-text PDF

Source
http://members.sirweb.org/members/misc/Jones.pdf
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S001448861000204
Publisher Site
http://dx.doi.org/10.1016/j.expneurol.2010.06.003DOI Listing
September 2010

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

J Clin Immunol 2010 Jan 10;30(1):99-105. Epub 2009 Sep 10.

Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-009-9327-3DOI Listing
January 2010

Trials of diminishing relapses for diminishing returns.

Authors:
Alasdair Coles

Lancet Neurol 2009 Oct 2;8(10):870-1. Epub 2009 Sep 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(09)70234-0DOI Listing
October 2009

Monoclonal antibodies in multiple sclerosis treatment: current and future steps.

Ther Adv Neurol Disord 2009 Jul;2(4):195-203

Department of Clinical Neurosciences, Addenbrooke's Hospital, Cambridge, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756285609337827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002635PMC
July 2009

Multiple sclerosis.

Authors:
Alasdair Coles

Pract Neurol 2009 Apr;9(2):118-26

University of Cambridge, Department of Neurology, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp.2008.171132DOI Listing
April 2009

Multiple sclerosis.

Lancet 2008 Oct;372(9648):1502-17

Department of Clinical Neurosciences, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(08)61620-7DOI Listing
October 2008

Campath-1H treatment of multiple sclerosis.

Neurodegener Dis 2008 ;5(1):27-31

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000109935DOI Listing
March 2008

The fragile benefit of BENEFIT.

Authors:
Alasdair Coles

Lancet Neurol 2007 Sep;6(9):753-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(07)70201-6DOI Listing
September 2007

Notes on the kidney and its diseases for the neurologist.

J Neurol Neurosurg Psychiatry 2007 May;78(5):444-9

Department of Clinical Neurosciences, University of Cambridge, Box 165, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp.2006.091991DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117828PMC
May 2007

The curious incident of disability in multiple sclerosis trials.

Authors:
Alasdair Coles

Lancet Neurol 2006 Nov;5(11):899-900

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(06)70585-3DOI Listing
November 2006

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

J Neurol 2006 Jan 27;253(1):98-108. Epub 2005 Jul 27.

Department of Clinical Neurosciences, Box 165, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-005-0934-5DOI Listing
January 2006

Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells.

Eur J Immunol 2005 Dec;35(12):3694-703

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.200526128DOI Listing
December 2005

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

Eur J Immunol 2005 Nov;35(11):3332-42

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.200535075DOI Listing
November 2005

Recurrent myelitis and optic neuritis in a 29-year-old woman.

Lancet Neurol 2005 Aug;4(8):510-6

Department of Clinical Neurosciences, University of Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(05)70143-5DOI Listing
August 2005

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.

Clin Neurol Neurosurg 2004 Jun;106(3):270-4

Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 2QQ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2004.02.013DOI Listing
June 2004

Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro.

Eur J Neurosci 2003 Nov;18(9):2527-37

Department of Neurology II, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1460-9568.2003.02917.xDOI Listing
November 2003

Case reports in The Lancet.

Lancet 2003 Apr;361(9364):1230

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(03)12946-7DOI Listing
April 2003

Multiple sclerosis.

Lancet 2002 Apr;359(9313):1221-31

Neurology Unit, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(02)08220-XDOI Listing
April 2002